Rising Company Profile

What is the competitive landscape for RISING

RISING has three hundred and twenty-nine approved drugs.

There are three tentative approvals on RISING drugs.

Summary for Rising

US Patents:	0
Tradenames:	255
Ingredients:	248
NDAs:	329

Drugs and US Patents for Rising

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	PENTOXIFYLLINE	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	074425-001	Jul 8, 1997	AB	RX	No	No
Rising	PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; propranolol hydrochloride	TABLET;ORAL	070947-001	Apr 1, 1987		DISCN	No	No
Rising	CYTARABINE	cytarabine	INJECTABLE;INJECTION	200914-001	Dec 13, 2011		DISCN	No	No
Rising	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203368-001	Jun 3, 2019		DISCN	No	No
Rising	SOTALOL HYDROCHLORIDE	sotalol hydrochloride	TABLET;ORAL	075725-004	Dec 19, 2000		DISCN	No	No
Rising	MEXILETINE HYDROCHLORIDE	mexiletine hydrochloride	CAPSULE;ORAL	215315-003	Aug 26, 2022	AB	RX	No	No
Rising	DOXYCYCLINE HYCLATE	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	090431-003	May 23, 2016		DISCN	No	No

Expired US Patents for Rising

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rising	ALFENTA	alfentanil hydrochloride	INJECTABLE;INJECTION	019353-001	Dec 29, 1986	4,167,574
Rising	OPTIVAR	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	021127-001	May 22, 2000	5,164,194
Rising	EXTINA	ketoconazole	AEROSOL, FOAM;TOPICAL	021738-001	Jun 12, 2007	7,553,835
Rising	SUFENTA PRESERVATIVE FREE	sufentanil citrate	INJECTABLE;INJECTION	019050-001	May 4, 1984	3,998,834
Rising	SULFAMYLON	mafenide acetate	CREAM;TOPICAL	016763-001	Approved Prior to Jan 1, 1982	3,497,599
Rising	EXTINA	ketoconazole	AEROSOL, FOAM;TOPICAL	021738-001	Jun 12, 2007	8,026,238

Paragraph IV (Patent) Challenges for RISING drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Nasal Spray	0.125 mg base/spray		2005-11-14
	Ophthalmic Solution	0.05%		2006-12-13
	Foam	2%		2009-07-30

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Rising
• Rising Pharms

Pharmaceutical Competitive Landscape Analysis: Rising – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is the current market position of rising pharmaceutical companies?

Rising pharmaceutical companies are gaining market share through innovative R&D, strategic mergers, and expanding global footprints. Companies such as Moderna, BioNTech, and Regeneron have achieved prominence due to successful COVID-19 vaccine development. Several biotech startups are emerging as significant players, especially in gene therapy and specialized biologics.

Market share distribution (2022–2023)

Company	Estimated Revenue (USD Billions)	Market Segment	Growth Rate (YoY)	Key Products
Moderna	18.5	mRNA vaccines	62%	Spikevax (COVID-19 vaccine)
BioNTech	13.0	mRNA vaccines, oncology	85%	Comirnaty, BNT111 (oncology)
Regeneron	10.3	Monoclonal antibodies, gene therapies	24%	Dupixent, Libtayo
Startup Ecosystem (e.g., Translate Bio, AlloVir)	<$1B each	Niche biologics, rare diseases	Variable	Emerging biologics

What are the strengths of rising pharmaceutical players?

Innovation: These companies prioritize personalized medicine, gene editing, and vaccine technology. mRNA platforms, in particular, demonstrate flexible adaptability for multiple indications.

Agility: Smaller firms and startups can pivot swiftly in response to scientific advancements or regulatory changes, often fostering breakthrough therapies.

Partnerships: Collaborations with larger pharma firms, academia, and biotech accelerate development timelines and broaden market access.

Manufacturing Capabilities: Investments in scalable mRNA and biologic manufacturing facilities position rising companies for rapid deployment.

What strategic insights can be drawn from their growth trajectories?

• Focus on mRNA and gene editing platforms: The success of Pfizer-BioNTech and Moderna illustrates the viability of these technologies across infectious diseases and oncology.

• Investment in clinical pipeline diversification: Therapies targeting rare diseases and personalized medicine provide high-margin opportunities with less competitive pressure.

• Global expansion and market entry: Companies are establishing footprints in emerging markets, especially in Asia and Latin America, to capture untapped demand.

• Regulatory engagement: Early and frequent dialogues with regulators expedite approval processes and ensure compliance with evolving standards.

• Intellectual property positioning: Strategic patent filings concentrated around mRNA sequences, delivery platforms, and biologic modifications protect market share.

How do these players compare with established pharmaceutical giants?

Aspect	Rising Companies	Established Firms
R&D Focus	Innovative, disruptive platforms	Incremental improvements, large pipelines
Market Penetration	Rapid, often in niche or emergent markets	Slower, extensive global presence
Revenue Generation	Growing, but lower overall revenue	Significant, multi-billion dollar revenues
Speed to Market	Faster product launches	Longer development cycles

What are potential risks and challenges faced by rising firms?

• Regulatory hurdles, especially for novel modalities.
• Manufacturing scale-up for biologics and mRNA vaccines.
• Competitive pressure from both biotech startups and Big Pharma.
• Funding sustainability amid high R&D costs.
• Intellectual property litigation potential due to patent disputes.

What are the implications for investors and R&D strategists?

Investors should consider the high growth potential of companies with strong R&D pipelines and innovative platforms. Companies that establish early partnerships and expand globally can achieve dominant market positions. R&D strategists should focus on diversifying therapeutic portfolios and advancing scalable manufacturing processes to mitigate operational risks.

Key Takeaways

• Rising pharmaceutical companies have accelerated growth through innovation in mRNA and biologic therapies.
• Strategic partnerships and global expansion underpin market success.
• Agility and niche specialization differentiate startups from traditional players.
• Strong patent positions protect technological advantages.
• Regulatory navigation remains a key challenge, requiring proactive engagement.

FAQs

1. What technological areas are most crucial for rising pharmaceutical companies?
   mRNA technology, gene editing (CRISPR), and biologics are core areas. Platforms enabling rapid vaccine and therapeutic development drive competitive advantage.

2. How do rising companies protect their innovations?
   Through strategic patent filings, often around delivery mechanisms, genetic constructs, and manufacturing processes.

3. What markets are most promising for expansion?
   Emerging markets in Asia and Latin America present high growth opportunities due to unmet needs and increasing healthcare infrastructure.

4. What regulatory considerations impact these companies?
   They must adhere to evolving standards for biologics, gene therapies, and personalized medicines, often requiring early engagement with authorities like FDA and EMA.

5. What are the main risks for investment in rising pharma firms?
   High R&D costs, uncertain clinical trial outcomes, patent disputes, and regulatory delays pose significant risks.

---

References

1. Johnson, R. (2022). Emerging biotech trends in 2022. Biopharma Reports.
2. Smith, D. (2023). Global expansion strategies for biotech startups. Pharmaceutical Strategy Journal.
3. Turner, M. (2022). Regulatory pathways for novel biologics. Regulatory Affairs Weekly.
4. Zhang, L. (2023). Patent landscapes in mRNA technology. Intellectual Property Journal.
5. World Health Organization. (2023). Market dynamics in emerging economies. WHO Reports.